1. Home
  2. CIK vs MNOV Comparison

CIK vs MNOV Comparison

Compare CIK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

SELL

Current Price

$2.30

Market Cap

127.8M

Sector

Finance

ML Signal

SELL

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.48

Market Cap

137.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
MNOV
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.8M
137.8M
IPO Year
1995
2004

Fundamental Metrics

Financial Performance
Metric
CIK
MNOV
Price
$2.30
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.25
AVG Volume (30 Days)
588.5K
★ 801.4K
Earning Date
01-01-0001
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,360,807.00
Revenue This Year
N/A
$78.20
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 194.15
52 Week Low
$2.29
$1.17
52 Week High
$2.90
$3.90

Technical Indicators

Market Signals
Indicator
CIK
MNOV
Relative Strength Index (RSI) 36.20 37.07
Support Level N/A $1.29
Resistance Level $2.40 $1.48
Average True Range (ATR) 0.03 0.16
MACD 0.00 -0.09
Stochastic Oscillator 9.06 0.01

Price Performance

Historical Comparison
CIK
MNOV

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. UBS Asset Management serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: